Allakos ALLK Stock
Allakos Price Chart
Allakos ALLK Financial and Trading Overview
| Allakos stock price | 0.33 USD |
| Previous Close | 3.31 USD |
| Open | 3.23 USD |
| Bid | 2.96 USD x 2900 |
| Ask | 3.12 USD x 1400 |
| Day's Range | 2.97 - 3.23 USD |
| 52 Week Range | 2.97 - 8.73 USD |
| Volume | 2.17M USD |
| Avg. Volume | 981.74K USD |
| Market Cap | 268.34M USD |
| Beta (5Y Monthly) | 0.40284 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
ALLK Valuation Measures
| Enterprise Value | 108.54M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.7222222 |
| PEG Ratio (5 yr expected) | -0.07 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.0554987 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.703 |
Trading Information
Allakos Stock Price History
| Beta (5Y Monthly) | 0.40284 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 8.73 USD |
| 52 Week Low | 2.97 USD |
| 50-Day Moving Average | 4.63 USD |
| 200-Day Moving Average | 5.71 USD |
ALLK Share Statistics
| Avg. Volume (3 month) | 981.74K USD |
| Avg. Daily Volume (10-Days) | 1.16M USD |
| Shares Outstanding | 86.56M |
| Float | 49.09M |
| Short Ratio | 10.06 |
| % Held by Insiders | 4.34% |
| % Held by Institutions | 89.55% |
| Shares Short | 6.51M |
| Short % of Float | 9.90% |
| Short % of Shares Outstanding | 7.52% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.048% |
| Return on Equity (ttm) | -63.35% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -154472000 USD |
| Net Income Avi to Common (ttm) | -151350000 USD |
| Diluted EPS (ttm) | -1.95 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 221.1M USD |
| Total Cash Per Share (mrq) | 2.54 USD |
| Total Debt (mrq) | 42.38M USD |
| Total Debt/Equity (mrq) | 16.62 USD |
| Current Ratio (mrq) | 10.275 |
| Book Value Per Share (mrq) | 2.937 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -135647008 USD |
| Levered Free Cash Flow (ttm) | -88489504 USD |
Profile of Allakos
| Country | United States |
| State | CA |
| City | San Carlos |
| Address | 825 Industrial Road |
| ZIP | 94070 |
| Phone | 650 597 5002 |
| Website | https://www.allakos.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 123 |
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Q&A For Allakos Stock
What is a current ALLK stock price?
Allakos ALLK stock price today per share is 0.33 USD.
How to purchase Allakos stock?
You can buy ALLK shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Allakos?
The stock symbol or ticker of Allakos is ALLK.
Which industry does the Allakos company belong to?
The Allakos industry is Biotechnology.
How many shares does Allakos have in circulation?
The max supply of Allakos shares is 90.52M.
What is Allakos Price to Earnings Ratio (PE Ratio)?
Allakos PE Ratio is now.
What was Allakos earnings per share over the trailing 12 months (TTM)?
Allakos EPS is -1.3 USD over the trailing 12 months.
Which sector does the Allakos company belong to?
The Allakos sector is Healthcare.
Allakos ALLK included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}